



LJWG CONFERENCE 2018

SEVEN YEARS TO HCV ELIMINATION: THE ROAD TO 2025

LIVERY HALL | GUILDHALL | LONDON
MONDAY 3 DECEMBER 2018

welcome

FROM **Dr Emily Finch and
Dr Suman Verma**

CO-CHAIRS

Dear colleagues,

Welcome to this year's annual conference of the London Joint Working Group on Substance Use and Hepatitis C, which is bigger and more exciting than ever.

With only 7 years to go until we reach our 2025 ambition to have effectively eliminated hepatitis C in London, we know there is a lot to do. There is a real sense of momentum and energy amongst people working in the field of hepatitis C at the moment and we want to harness this today to drive forward action in drugs services, prisons, general practice, hospitals, pharmacies and communities across London.

To achieve our shared goal, we need your help. We hope you will be inspired by the brilliant speakers and delegates here today, and will gain new ideas from the in-depth workshops and good practice posters. We would like everyone here today to take away at least one practical idea or action for their organisation or practice to ramp up efforts to tackle hepatitis C.

Please keep in touch, share your reflections and ideas with us after the conference and work with us. You can sign up to our mailing list by emailing info@ljwg.org.uk and follow us on Twitter, @LJWGHepCandSM.

**Dr Emily Finch
& Dr Suman Verma**

Co-chairs, LJWG



A message from:

Steve Brine MP

*Parliamentary Under Secretary of State
for Public Health and Primary Care*

I would like to congratulate the London Joint Working Group for holding this conference as it provides a unique opportunity for a range of experts to focus on how best to find, support and treat people infected with hepatitis C in London. In addition, through its instrumental work this group has demonstrated innovative approaches to overcoming a range of challenges that will be recognised nationwide.

The pivotal role that community pharmacies play in the provision of services to communities across London is something I recognise and having visited one of the LJWG's pilot hepatitis C pharmacy testing projects, I can see the enormous value of providing hepatitis C testing and the potential of providing treatment through the same route. These points of contact with people who inject, or have previously injected, drugs provide an ideal opportunity to test this vulnerable population for hepatitis C.

I look forward to hearing the outcome of Phase 2 of the pharmacy pilot project using point-of-care testing that will enable test results to be available within an hour and also the work in Manchester and Birmingham to look at the feasibility of rolling this initiative out more widely across England.

 #LJWG2018

The London Joint Working Group on Substance Use and Hepatitis C

THE London Joint Working Group on Substance Use and Hepatitis C (LJWG) is a group of expert clinicians and patient advocacy and voluntary sector leads, working in collaboration with a wide group of stakeholders with the common goal of implementing an integrated plan to drive improvements in the prevention, diagnosis, treatment and outcomes of hepatitis C in people who use drugs, and reduce the spread of the virus. LJWG welcomes new partners and collaborators who share their vision and goals.

The members are:

Dr Kosh Agarwal

Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies, King's College Hospital, London

Dr Ashwin Balabhadra

GP with Special Interest in the Management of Substance Misuse and Hepatitis in Primary Care

Dr Ashley Brown

Consultant Hepatologist at St. Mary's and Hammersmith Hospitals in London and Honorary Senior Lecturer at Imperial College London.

Janet Catt

Lead Nurse, Specialist Practice at the Royal Free Hampstead NHS Trust, London.

Vivienne Evans

Chief Executive of Adfam

Dr Emily Finch (co-chair)

Consultant Addiction Psychiatrist at the South London and Maudsley NHS Foundation Trust, London

Rachel Halford (vice chair)

Chief Executive of The Hepatitis C Trust

Dr Magdalena Harris

Qualitative Sociologist, London School of Hygiene and Tropical Medicine

Sarah Hart

Senior Commissioner for Substance Misuse and Sexual Health services within Public Health in Haringey Council

John Jolly

Chief Executive of Blenheim

Professor William Rosenberg

Professor of Hepatology at University College London

Dr Suman Verma (co-chair)

Consultant Hepatologist at the Chelsea and Westminster Hospital and an Honorary consultant at the Royal Brompton Hospital

The group is facilitated by;

Dee Cunniffe

LJWG Policy Lead

programme

The programme and timings are subject to change.

MORNING PLENARY SESSION 1

Chaired by Dr Emily Finch,
co-chair of the LJWG and Consultant Addiction
Psychiatrist at South London and Maudsley

9.20 Welcome

*by Hugh Morris,
Chair of the London Drug
and Alcohol Policy Forum*

9.25 Living with and after hepatitis C, including video screening, 'Moving on with my life: getting cured of hepatitis C'

*Rachel Halford,
CEO of The Hepatitis C Trust*

9.35 Addressing the health inequalities issue of hepatitis C in London

*Yvonne Doyle
Regional Director for Public Health
England, London*

9.45 The State of the Nation

*Dr Graham Foster,
Clinical Lead Hepatitis C, NHS England*

10.00 The changing landscape and the future of hepatitis C treatment

*Janet Catt,
Nurse Consultant, Kings College*

*and Chris Laker,
Peer Support Worker (South London),
The Hepatitis C Trust*

10.10 LJWG pharmacy testing and treatment overview

*Dr Suman Verma,
Consultant Hepatologist,
Chelsea and Westminster Hospital*

10.25 Q&A with panelists

chaired by Dr Emily Finch

10.40 Coffee break / posters

MORNING PLENARY SESSION 2

Chaired by Dr Suman Verma,
co-chair of the LJWG and Consultant Hepatologist
at Chelsea and Westminster

11.00 Action in London

*Susan Hall AM,
London Assembly Member*

11.10 Economic evaluations of case finding for people who inject drugs and have hepatitis C

*Professor Peter Vickerman,
Professor of Infectious Disease Modelling,
University of Bristol*

*and Dr Zoe Ward,
Senior Research Associate in Infectious
Disease Modelling, University of Bristol*

11.20 Joining the dots: the importance of joining data processes in pathways

Dr Emily Finch

*and Dr Katherine Morley,
Senior Lecturer, National Addiction Centre,
Kings College London*

11.30 Q&A with panelists

chaired by Dr Suman Verma

11.40 Interactive plenary session: Lessons from HIV campaigns and micro-elimination plans

*With Professor Mark Nelson,
Consultant Physician at
Chelsea and Westminster Hospital*

*and Dr Andy Ustianowski,
Chair of the British Viral Hepatitis Group
and Consultant in Infectious Diseases,
North Manchester General Hospital.*

*Facilitated by Nick Rodger,
Managing Partner at Consortio Healthcare.*

12.15 Video screening, 'The impact of hepatitis C'

introduced by Dr Suman Verma

12.20 Lunch and posters

WORKSHOPS

1.00 Workshop Session One

7 years to go - what do we need to do?

WORKSHOP 1 Main Plenary Hall

7 years to go – What’s happening and what more needs to happen in drugs services?

- **Chaired by Dr Emily Finch and with guest speakers:**
- John Jolly, Chief Executive of Blenheim
- Jackie Howe, Regional Hepatitis C Coordinator, CGL
- Helen Hampton, Lead Clinical Nurse for Blood Borne Virus, Addaction
- Stuart Smith, Director of Community Services, The Hepatitis C Trust

WORKSHOP 2 East Crypt

7 years to go – What’s happening and what more needs to happen in pharmacies?

- **Chaired by Dr Suman Verma and with guest speakers:**
- Rekha Shah, LPC Lead, Kensington and Chelsea
- Michael O’Sullivan, Junction Pharmacy Brixton, LJWG pilot pharmacy
- Pritpal Thind, Community Pharmacist, Sonar Informatics
- Dr Zoe Ward, Senior Research Associate in Infectious Disease Modelling, University of Bristol

WORKSHOP 3 Committee Room 3

7 years to go - What’s happening and what more needs to happen in prisons?

- **Chaired by Rachel Halford and with guest speakers:**
- Janet Catt, Nurse Consultant, Kings College
- Dr Mike Kelleher, Consultant Psychiatrist, Lambeth Drug and Alcohol Service
- Professor Peter Vickerman, Bristol University
- Adrian Perks, Health and Justice Clinical Programme Manager, NHS England

WORKSHOP 4 West Crypt

7 years to go - Finding the undiagnosed who are not engaged with services.

- **Chaired by Charles Gore with guest speakers:**
- David Mackintosh, London Drug and Alcohol Policy Forum
- Diarmaid Crean, Digital Deputy Director Public Health England
- Fraser Woodward, Head of Communications, Engagement and Partnerships, Specialised Commissioning, NHS England
- Kate Pogson, Head of Health, MHP Communications

2.15 Workshop Session Two

Same options as session one

WORKSHOP 1 Main Plenary Hall

7 years to go – What’s happening and what more needs to happen in drugs services?

WORKSHOP 2 East Crypt

7 years to go – What’s happening and what more needs to happen in pharmacies?

WORKSHOP 3 Committee Room 3

7 years to go - What’s happening and what more needs to happen in prisons?

WORKSHOP 4 West Crypt

7 years to go - Finding the undiagnosed who are not engaged with services.

3.15 The road to elimination: reflections on 18 years at The Hepatitis C Trust and the future for hepatitis C

Charles Gore, former CEO of The Hepatitis C Trust and former President of the World Hepatitis Alliance

3.30 Summary and call to action with video screening, ‘We have a moment now: eliminating hepatitis C in London’

by Dr Emily Finch and Dr Suman Verma

4.00 Close of conference business.

You are invited to stay to network and share experiences until 5pm.

good practice posters

🐦 #LJWG2018

We are pleased to showcase the following posters:

Hepatitis C (HCV) testing and referral for people actively injecting drugs (PWIDs) in Needle and Syringe Provision (NSP) Community Pharmacies in London

Author *Dr. Suman Verma*

Factors associated with a current HCV infection among people who inject drugs in England, Wales and Northern Ireland in 2017

Authors *Flora Stevens, Claire Edmundson, Rachel Glass, Katy Sinka, Stephanie Migchelsen*

From peer-based to peer-led – redefining the role of peers across the hepatitis C care pathway: HepCare Europe

Authors *Julian Surey, Dee Menezes, Marie Francis, John Gibbons, Binta Sultan, A. Miah, A. Story, I Abubakar*

Raising awareness across Drug Treatment Services, Prisons and At-risk groups

Author *Rebecca Dandridge*

The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK.

Authors *Zoe Ward and Linda Campbell, Julian Surey, Steven Platts, Rachel Glass, Matthew Hickman, Alastair Story, Peter Vickerman*

Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a Peer Advocacy intervention.

Authors *H Stagg, M Francis, J Surey, I Abubakar*

Are children and young people with vertically acquired chronic hepatitis C infection and whose mothers have a history of injecting drug use, accessing and receiving successful treatment?

Authors *Sarah Tizzard, Anil Dhawan, Ivana Carey, Sanjay Bansal*

Onsite treatment clinic at a Change Grow Live community drugs service in Newham

Author *Jackie Howe*

Video observer treatment for hepatitis C patients – improving adherence and outcomes: Hepcare Europe

Authors *A Story, J Gibbons, M Francis, J Surey*

plenary speakers and workshop leads

Dr Suman Verma

co-chair of the LJWG

Dr. Suman Verma is a Consultant Hepatologist at the Chelsea and Westminster Hospital and an Honorary consultant at the Royal Brompton Hospital. Prior to this she was a Locum Consultant and Senior Clinical Fellow at the Institute of Liver Studies at King's College Hospital.

She trained in Medicine at Edinburgh and Cambridge Universities and completed a PhD in Immunology. Following graduation, Dr. Verma has worked in major liver transplant units at King's, Birmingham and Cambridge. During this time, she developed research and specialist interests in the management of chronic viral hepatitis, end-stage liver disease and liver transplantation.

Dr. Verma was involved in the NHSE Early Access Program for Hepatitis C and co-ordinated the Early Access Exceptional Case Panel multi-disciplinary meeting. Dr. Verma has been a sub-investigator on numerous clinical trials with the new antivirals, and is a member of the BASL, EASL and AASLD.



Prof Graham Foster

Clinical Lead for Hepatitis C, NHS England

Professor Foster is the Clinical Lead for the Hepatitis C Operational Delivery Networks (ODNs) for England. He is Professor of Hepatology at Queen Marys, University of London and a consultant at Barts and The London in East London. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992.

Professor Foster has a long standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities and novel therapies for this disease. He supervises a laboratory research program investigating the mode of action of the different type I interferons and novel replication models for hepatitis C.

He is the sub-editor of The Journal of Viral Hepatitis and has published widely in the field of viral liver disease.

He is a past President of BASL, Chairman of the HPB CRG, clinical lead for the HCV networks in England and a member of a number of patient advocacy groups.



Dr Emily Finch

co-chair of the LJWG

Dr Finch is a Consultant Addiction Psychiatrist at South London and Maudsley and Clinical Director, Addictions Clinical Academic Group (CAG). She is a member of the Royal College of Psychiatrists Addictions Executive, the Advisory Council on the Misuse of Drugs (ACMD) and the working group revising the DH guidelines on the management of substance misuse.

From 2004 to 2007 Emily was the Clinical Team Leader at the NTA where she took a lead in the clinical aspects of national drug policy and in liaising between the NTA and professionals working in the field; she was also part of the secretariat for the 2007 Drug Misuse and Dependence: Guidelines on Clinical Management.

She is a tutor, lecturer and examiner on the MSc in Addiction studies and is an experienced expert witness in family and criminal cases. Her research interests include the outcome of treatment for opiate users and alcohol users, parents who use drugs and alcohol and dual diagnosis. Emily is a Trustee of Alcohol Concern and Chaired of the NICE quality standards group for substance misuse in 2012.



Rachel Halford

Chief Executive of The Hepatitis C Trust

Rachel has over 20 years' experience of working with people at high-risk of viral hepatitis, and liver disease generally – the homeless, prisoners, substance users and migrants.

The past 18 years of which have been in senior management roles within the voluntary/ NGO sector. Passionate about equality and human rights, Rachel joined The Hepatitis C Trust in 2015 as Deputy CEO, in July 2018 Rachel took over the role of CEO.

Before joining the Trust she was CEO of Women in Prison, a national UK campaigning organisation that provided support and advocacy for women affected by the criminal justice system.

Diagnosed with Hepatitis C in 1998, Rachel completed Interferon treatment in 2007 clearing the disease.



Janet Catt

MSc RN. Non-medical prescriber.

For the past 13 years' my experience has been working in the field of viral hepatitis/hepatology, both in a community/countywide setting and including x2 tertiary referral centres in London, including Prisons. My main focus more recently has been to improve patient experience amongst a wide range of service users and providers, and to develop innovative projects that will enable greater access to care for all patient groups – challenging but very rewarding.

I am a founder member of the steering group for ISH (Interactive Summit on Hepatitis). I also sit on the London Joint Working Group for Substance Misuse and Hepatitis C (www.ljwg.org.uk). I have been invited to speak at conferences throughout the UK and internationally, which include the Nurse Forum EASL, the BASL Nurse Forum, the Nursing World Conference and the South American Viral Hepatitis Conference in Sao Paulo, Brazil, 2013.



Hugh Morris

Chairman of the London Drug and Alcohol Policy Forum

Hugh is currently a consultant to a number of City institutions. Previously he was Sales Director for TORI Global, VP for Europe Financial Services for Genpact, CEO of Laureate Legal Services, Director at Xchanging plc and a senior partner at Accenture. He has worked in the City for over thirty-five years as a consultant to the insurance, banking, securities trading, commodities trading and legal sectors. He was elected to the Court of Common Council for the City of London in December 2008. He is a Deputy for Aldgate Ward and holds a number of other City of London Corporation posts. He was elected chairman of the London Drug and Alcohol Policy Forum in April 2009.



Yvonne Doyle

Regional Director for Public Health England, London

Yvonne Doyle joined PHE in December 2012. Yvonne Doyle qualified as a doctor and has worked in senior roles in the NHS and Department of Health, and in the academic and independent sectors. Since 2013 she provides leadership for health, prevention of ill health, health protection and reduction of inequalities at city-wide level to the population of London. Her recent international work on behalf of the Mayor of London has been to accelerate London's ambition to become the healthiest and fairest global city. She has acted as an adviser to the WHO on Healthy Cities and has recently been appointed a Companion of the Order of the Bath for services to Public Health. As Regional Director for PHE London she ensure the quality, responsiveness and consistency of the services PHE centres provide. She also has an assurance role for emergency planning and response and is responsible for workforce development across the wider public health system.



Chris Laker

Peer Support Worker (South London), The Hepatitis C Trust

Chris has been working in the drug and alcohol field for over 11 years in a variety of roles and really enjoys his work. Chris spent 7 years as Coordinator of a mobile needle exchange, part of this was testing for BBV Assessments. Chris explains, 'It was always a problem when we had a positive for hep C as the pathway and treatment were inadequate for the particular active client group I was engaging with and as a worker I felt quite powerless.'

Chris joined The Hepatitis C Trust just over a year ago and started setting up a clinic with Janet Catt at King's College Hospital. Because of the new pathway in the ODN Chris now engages with the same client group as before and is able to offer solid solutions and explain to patients exactly what to expect from the treatment and the process. "I have seen life changing results for the individuals that I have been able to support with the help of the team at The Trust and Kings Hospital"



Susan Hall AM

London Assembly
Member

Susan was elected as a Harrow Councillor for Hatch End Ward in 2006. She was given a cabinet position responsible for the environment and community safety in 2007 and became Deputy Leader of the group in 2008. Susan became Leader of the group in 2010 and she took over as Leader of the hung council in 2013 returning to opposition Leader in 2014. She is now a London-wide Assembly Member and Deputy Chair of the Health Committee.



Dr Katherine Morley

Lecturer National
Addiction Centre
Kings College London

Dr Morley is based at the National Addiction Centre at the Institute of Psychiatry, Psychology and Neuroscience. Prior to joining the NAC she worked at the Centre for Molecular, Environmental, Genetic and Analytic Epidemiology at the University of Melbourne, the Department of Human Genetics at the Wellcome Trust Sanger Institute, and the Department of Epidemiology at University College London.

Kate works on a range of topics related to substance use and psychiatric epidemiology, but she is mainly focused on prognosis research, particularly using linked electronic record data provided by the NIHR Maudsley Biomedical Research Centre. She is a Consultant Epidemiologist for the Society and Ethics Research Group at the Wellcome Genome Campus, leads the Research Methods, Critical Appraisal, and Statistics module for the MSc in Addiction Studies, and also teaches on the Prognosis Research: Concepts, Methods and Clinical Application summer school at Keele University.



Nick Rodger Managing Partner – Consortio Healthcare

Nick has more than 20 years' experience in marketing, sales and communication roles within the pharmaceutical / healthcare industry, working both 'in-house' and at several agencies. Nick has also supported other 'service' companies and charities to understand their goals, critical success factors and objectives to create their positioning / mission statement within their sector.

When managing cross-functional teams, Nick believes it is important to combine strategic thinking with a tactical and solutions-focused delivery to achieve agreed results. Nick also believes that, "A well-thought-through and well-executed project is only possible with a cohesive team behind it, so the ability to work multi-functionally is critically important!"

Nick has developed skills and learning to allow him to create, deliver and measure the success of tactical and operational plans, at all levels, whilst ensuring they support the organisation's strategic and commercial direction, whoever they are and whatever they are trying to achieve.



Dr Zoe Ward

Senior Research
Associate in Infectious
Disease Modelling,
University of Bristol

I am a mathematical biologist interested in infectious disease dynamics and epidemiology. I am interested in using mathematical approaches to inform policy decisions and suggest further avenues for biological research.

I am currently working on models of hepatitis C virus in populations of people who inject drugs and investigating the cost-effectiveness of case-finding and linkage to care interventions for HCV treatment. Work in this area includes three cost-effectiveness analyses: a linkage to care intervention through drug treatment centres in England, HCV treatments at a needle exchange in Scotland and a screening and linkage to care intervention using a mobile outreach unit and peer support.



Dr Andy Ustianowski

Chair of the British
Viral Hepatitis Group
and Consultant in
Infectious Diseases,
North Manchester
General Hospital.

Dr Ustianowski is a consultant physician in Infectious Diseases and research lead at the Regional Infection Unit, North Manchester General Hospital (one of the largest treatment centres for blood-borne viruses in the UK).

His research unit has been involved in most of the pivotal studies of the HCV DAAs and also some of the early phase studies for the newer HBV agents. He has been chair of the British Viral Hepatitis Group, part of guideline writing committees for the British HIV Association & other bodies, lectures widely on hepatitis, HIV & related topics, and is part of several national and international educational steering groups. He set up and was co-lead of a regional Hepatitis C Operational Delivery Network (ODN) and was previously on the NHS England Clinical Reference Group (CRG) responsible for Hepatitis C. He conceived and remains the clinical lead for the Greater Manchester Hepatitis C Elimination Programme

He graduated from Guy's Hospital, London, and subsequently trained in Infectious Diseases, Tropical Medicine, HIV and General Medicine in the London region.



Dr Mark Nelson

Consultant Physician Chelsea and Westminster Hospital

Dr Nelson is a consultant physician at the Chelsea and Westminster Hospital, London. He trained at Jesus College, Cambridge and Westminster Hospital medical school from where he qualified in 1986. He was appointed Consultant Physician at this hospital in 1991 and a senior lecturer at Imperial College Medical School in 1996. Since that time he has built a large HIV practice with a special interest in HIV in patient care, co-infection with hepatitis B and C and the clinical utility of new antiretroviral agents. He is presently the lead for HIV in patient and day case care Dr Nelson sits on the Executive Committee of the British HIV Association where he is co-chair of the guidelines committee for opportunistic infections and for hepatitis C. He is a member of the Guidelines Committee for Malignancy and for HIV transmission. He was chair of the BHIVA hepatitis special interest group and the newly elected chair of the BHIVA science and education committee. He is a trustee of several charities associated with HIV including the International Association of Physicians in AIDS care (IAPAC) and St Stephens AIDS Trust, a charity committed to the improvement of life for all those living with HIV where he is head of overseas development and education. He is now devoting most of his charitable time to GREENSHOOTS where he is establishing HIV treatment networks in Burma. He has been awarded a visiting professorship at the Aga Khan Hospital, Nairobi, Kenya and most recently the certificate of merit by the government of Vietnam.



Dr Peter Vickerman

Professor of Infectious
Disease Modelling
University of Bristol

Peter Vickerman is a Professor in infectious disease modelling at the University of Bristol. He has 25 years' experience in infectious disease modelling. His research focuses on the use of mathematical modelling to help understand the transmission of different infectious diseases and impact and cost-effectiveness of prevention measures. Specific expertise focuses on the transmission of HIV, HCV and other STIs amongst different high-risk groups including female sex workers, men who have sex with men and injecting drug users. He has extensive experience of conducting collaborative research with organisations in Asia, sub-Saharan Africa, Eastern Europe and the UK. He has contributed to numerous international advisory groups (including WHO, U.S. Centre for Disease Control and Prevention, U.S. National Institute of Health, NICE Public Health guidance committees and Public Health England).



Charles Gore

Executive Director,
Medicines Patent
Pool and former CEO
of The Hepatitis C
Trust and the World
Hepatitis Alliance

Charles Gore is the Executive Director of the Medicines Patent Pool. He took up the post in July 2018 following a career in patient representation and public health advocacy.

He was diagnosed with hepatitis C in 1995 and cirrhosis in 1998. In 2000 he set up The Hepatitis C Trust in the UK which he ran for 18 years. In 2002 he was treated and cured of the virus.

He helped create the European Liver Patients Association and was its first President in 2004. In 2007 he established the World Hepatitis Alliance and was President until December 2017. As a result of advocacy by the Alliance, WHO adopted successive viral hepatitis resolutions in 2010, 2014 and 2016, culminating in endorsement of the goal of eliminating hepatitis B and C by 2030.

In addition to direct advocacy with over 50 Ministries of Health, Charles has led on advising countries on finding sustainable domestic financing for hepatitis programs. Charles also sits on a number of national and international advisory bodies including the WHO Director-General's HIV and Hepatitis STAC and has been a member of all the WHO guideline development groups on testing and treating viral hepatitis.



delegates

Adam Sheard Change Grow Live	Claire Smith RFH	Fulya Yahioğlu Enfield Council Public Health	John Gibbons Groundswell	Dr. Mark Nelson Chelsea & Westminster Hospital	Philippa Pristera Imperial College London	Sarah Hodgson KCH & Lambeth Addiction Service
Adrian Perks NHS England	Claire Robbins Release	Funda Sinan KCH	John Jolly Blenheim	Mark Hopkins Barts Health Trust	Phillip Bennett-Richards The Aberfeldy Practice	Sarah-Jo Cunningham Bradford Teaching Hospitals
Agnieszka Tolwiska CNWL NHS FT	Claire James Change Grow Live	Gail Robinson Change Grow Live	Johnathan Occlleshaw Change Grow Live	Martel Junior Johnson Addaction	Pitchy-Ann Vicente KCH ACT	Sean Cox The Hepatitis C Trust
Ahmed Mamoun Mohammedahmed Balout University of Gothenburg - MPH Student	Claire Whittleton Change Grow Live	Gary Slegg NHS England	Jon Derricot Film Maker	Martin McCusker Lambeth Service User Council	Princess Glover Princess Chambers	Shafiqat Asif Private
Aidan Ryllatt Principle Consulting	Claire Rodger Consortio Healthcare	Gary Sutton Release	Joseph Kean Change Grow Live	Mary Chiyanike Change Grow Live	Pritpal Thind Caregrade Pharmacy	Shailesh Thakrar My Pharmacy
Aisling Considine Kings College Hospital	Dan Williams Release	Gelyn Lopez Sabatier Care Provider	Jude Adams Lambeth Service User Council	Mavis Mensah HMP Downview Prison	Rachael Sadegh London Borough of Tower Hamlets	Sharon O'Donnell Change Grow Live
Aisling Considine Kings College Hospital	Danielle Mervyn WDP Square Mile Health	George Sideserf CNWL/Phoenix Futures	Julia Sheehan The Hepatitis C Trust	Meena Parekh NHS	Rachel Halford The Hepatitis C Trust	Sher Ali Ullah Healthwatch Tower Hamlet
Ala Miah Groundswell	Danny Morris The Hepatitis C Trust	Georgianan Palmes West Hertfordshire Hospitals NHS Trust	Julia Gallagher Change Grow Live, Northamptonshire	Mehendra Seegum SABP	Rachel Roche Public Health England	Shona Handley The Beresford Project - Community Drug and Alcohol Team
Alan Bellamy SLAM	Danny Waites Lewisham Council	Georgina Ireland Public Health England	Julian Surey Change Grow Live	Melanie Getty McManus Aurora	Rachel Storr Change Grow Live	Simon Brasch Just Treatment
Aleksandar Milovanovic Change Grow Live	Darren Thomas Forward Trust	Georgina Storey PCP	Karen Kemp Turning Point	Mercy Nimako Turning Point	Rachel Thorn Heathcock Public Health England	Simona Allen Haringay Advisory Group on Alcohol
Alex Boyd Blenheim	David Parker-Radford The Queen's Nursing Institute	Geraldine O'Brien Kings College Hospital	Karim Dar CNWL NHS Foundation Trust	Michael O'Sullivan Junction Pharmacy	Rae Cook AdFam	Sital Shah Kings College Hospital
Alison Pearce GLA	David Robertson King's College Hospital	Grace Cameron Central and North West London NHS Foundation Trust	Karthik Paranthaman Public Health England	Michelle Brown Change Grow Live	Raushia Coles Inclusion	Sonia Chemlal London School of Hygiene and Tropical Medicine
Amanda Inniss Care UK	David Gilliver Mr	Professor Graham Foster NHS England	Kate O'Brien Camden and Islington NHS Trust	Mick Mcmanus Substance Misuse Strategy Team	Raychel Peters Council	Sophie Ikuzwe St Georges Hospital
Amy Blake Change Grow Live	Debbie Simmons Greenwich Cluster Prisons/Oxleas NHS Trust	Hayley Mason NHS England	Dr. Katherine Morley Kings College London	Dr. Mike Kelleher Lambeth Drug & Alcohol Service	Rebecca Giddings Public Health England	Stephen Bahooshi Croydon Council
Andrew Calvis Contractor	Debbie Butler Change Grow Live East Sussex	Hayley Ward MSD	Katherine Dallas Change Grow Live	Miranda Mindlin South London Health Protection Team	Rebecca Dandridge Gilead	Stephen Heaton Wandsworth Community Drug and Alcohol Service
Andrew Casey St Mungo's	Deborah Cok Cepheid	Helen Oluosamokun Change Grow Live	Katherine Dallas Change Grow Live	Miriam Mohamed Change Grow Live	Rebekah McKinley The Hepatitis C Trust	Steven Blake HCT
Andrew Gregory Gilead	Denise Burridge Change Grow Live	Helen Hampton Addaction	Kathy Cheung Camden Health Improvement Practice	Monique Tomlinson Exchange Supplies	Rekah Shah LPC	Stuart Smith HCT
Dr. Andy Ustianowski North Manchester General Hospital	Dev Matadeen Change Grow Live	Helen Boothman St George's NHS Foundation Trust	Katie Portou North Middlesex Hospital	Nabeel Sheraz GLA	Rita Rajababoo NHS	Dr. Suman Verma Co-chair, London Joint Working Group on Substance Use and Hepatitis C
Angela Hart Lewisham & Greenwich NHS Trust - QE site	Dezlee Dennis DAAT	Hikaru Bolt Public Health England	Kevin Darbyshire The Royal Free	Naomi Westlake SLAM	Roger Pebody NAM Aidsmap	Sundeep Hyare Change Grow Live
Annabelle Boeuttou Aurora	Diane Rapley Change Grow Live	Ikenna Obianwa London Borough of Redbridge	Kim Osborne Turning Point	Natalie Wood AbbVie	Romanie Westwood Royal Surrey County Hospital	Susan Hall Assembly Member
Annette Seth - Smith Inclusion	Dimitar Tonev HCV research UK	Ina New CNWL NHS Trust	Krishna Mohan Ganganine ABMU Health Board	Nathan Motherwell HCT	Rose Wyatt North Middlesex University Hospital	Sushma Patel Cepheid
Archibald Gwshavanhu Kingsong Wellbeing Service	Dolores Cunniffe London Joint Working Group on Substance Use and Hepatitis C	Indra Macfarlane Change Grow Live	Laila Indiongo North Middlesex University Hospital	Naz Mahmud Change Grow Live	Rosie Mundt-leach SLAM	Tandile Mkiye Careuk
Archie Christian The Hepatitis C Trust	Donna Hewer Change Grow Live	Indra Macfarlane Change Grow Live	Laura Robertson Change Grow Live	Nelson Sekimpi Church	Rosy Flexer SLAM	Tessa James Turning Point
Ariella Tziona Williams Change Grow Live	Douglas Macdonald North Central London ODN	Irene Guerrini SLAM	Lawrence Asea CNWL	Niamh Donnelly Cranstoun	Ruby Osorio CNWL NHS Foundation Trust	Thawab Al-Chalabi Lewisham University Hospital
Ashleigh Scott AbbVie	Dr David Aitchison NHS	Jackie Howe Change Grow Live	Linus Okorie CNWL- ARC Hounslow	Nick Rodger Consortio Healthcare	Samantha Fletcher South London and Maudsley NHS Foundation Trust	Tina Shah Royal Free NHS Trust
Ashwin Balabhadra The Staunton Medical Group	Dr David Aitchison NHS	Jackie Harding Change Grow Live	Lisa Bowen Change Grow Live	Nicola Tweed Change Grow Live	Samantha Packham Change Grow Live	Tracey Reed Inclusion Substance Misuse
Asim Humayun AbbVie	Dympna McLaughlin SLAM	Jacqui F-Kwabi Change Grow Live	Lisa Gould Change Grow Live	Nikki Francis Change Grow Live	Sandra Pilcher East Kent Hospitals University NHS Foundation Trust	Urte Macikene Principle Consulting
Becca Walker Build on Belief	Eddie Meyers The Hepatitis C Trust	Jacqui F-Kwabi Change Grow Live	Liz McDonnell SLAM	Niomie Cartwright Change Grow Live Spectrum	Sara Hemming Lewisham & Greenwich NHS Trust	Veronica Cook AdFam
Becky Hug Principle Consulting	Edith Barber Barts Health	James Smith CNWL NHS Foundation Trust	Lois White Inclusion	Nnenna Ekeke Royal Free Hospital London	Sarah Montague King's College Hospital	Vicki Lent MPFT
Ben Blackmun CNWL NHS Trust	Edith Barber Barts Health	James Read MSD	Louise Eales Medway Maritime Foundation Trust	Ogechi Comfort Onwuchekwa HMP Thameside	Sarah Khalifeh LBTH Drug & Alcohol Action Team	Vicky Franks Change Grow Live
Beverly Edwards St George's NHS University Foundation Trust	Elizabeth Lines STARS/Change Grow Live	Jane Cox London Joint Working Group on Substance Use and Hepatitis C	Louise Hansford Inclusion	Olivia Auger Medway Maritime Foundation Trust	Sarah Tizzard King's College Hospital NHS Foundation Trust	Victoria Borwick RBKC
Binta Sultan UCL	Ellie Whitlock Principle Consulting	Jane Eastaway SLAM NHS Foundation Trust	Lyn Porter Change Grow Live, Southend	Owain Ashworth SLAM	Sarah Hart Haringey Council	Victoria Black AbbVie
Bridget O'Dwyer Harrow Public Health	Eloina Mortimer Change Grow Live	Jane Shea The Hepatitis C Trust	Madeline Kenley Community Options	Oyinkan Akinseye Change Grow Live	Paul Salmon SLAM	Yvonne Dawes The Royal Surrey County Hospital
Brigid Hamilton Better Lives	Dr. Emily Finch Co-chair, London Joint Working Group on Substance Use and Hepatitis C	Janet Catt Kings College Hospital	Magdalena Rocko KCH	Paula Bevan London Borough of Hackney	Penny Bevan London Borough of Hackney	Yvonne Doyle Public Health England
C Collingwood AdFam	Emma Burke Public Health England	Jayne Bailey Cepheid	Maggie Jager AbbVie	Pete Dunger Forward Trust	Professor Peter Vickerman University of Bristol	Zena Phillips Change Grow Live
Carola Sander-Hess Inclusion MPFT	Felice Cartz The Aberfeldy Practice	Jayne Copley Change Grow Live	Margarida Faria Change Grow Live, Southwark	Sarah Stennett St Georges	Sarah Secker-Barker Speaker	Dr. Zoe Ward University of Bristol
Charles Gore Medicines Patent Pool	Feyi Abudu Change Grow Live	Jens Wilde Addaction	Marie Moore Bedford Hospital	Sarah Secker-Barker		
Charlotte Newman Ms	Fiona Mackison NHS England Specialised Commissioning South	Jo Markham NHS	Marie Francis University College London			
Chinedu Uzoehina Change Grow Live	Fiona O'Dell St.Mungo's	Jo Clarke KHP-Homeless Pathway Team	Mariyana Badova CNWL			
Chris Kojie Change Grow Live	Flora Stevens Public Health England	Jody Lombardini CNWL NHS FT				
Chris Laker The Hepatitis C Trust	Fran Holgate Blenheim	Joel Petty Inclusion				



#LJWG2018

our sponsors and partners

#LJWG2018

abbvie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

For more information about AbbVie, please visit us at www.abbvie.co.uk.

GILEAD

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific

Cepheid

A better way.

Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer. www.cepheidinternational.com.

For more information, please visit www.cepheidinternational.com.

Adfam

Families, drugs and alcohol

Adfam is the national charity working to improve life for families affected by drugs and alcohol. Our vision is that anyone affected by someone else's drug or alcohol has the chance to benefit from healthy relationships, be part of a loving and supportive family and enjoy mental and physical wellbeing. Drug and alcohol use can threaten and ultimately destroy family relationships and wellbeing. We empower family members and carers, support frontline workers and influence decision-makers to stop this happening.

MSD

INVENTING FOR LIFE

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programmes and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world.

For more information, visit www.msd-UK.com and connect with us on Twitter @MSDintheUK.

THE HEPATITIS C TRUST

The Hepatitis C Trust is the national UK charity for people affected by hepatitis C. It began operating in 2001 and has offices in London and Falkirk. It is patient-centred and patient-run: almost all of its trustees, paid staff and volunteers either have hepatitis C or have cleared it.

The Trust's mission is to reverse the death toll caused by hepatitis C in the UK until no-one dies from this preventable and treatable disease and, ultimately, it is all but eradicated in this country. To achieve this the Trust runs a range of projects and services that fall broadly into 5 areas: information, support, representation, awareness raising and research.

To find out more about the work of The Hepatitis C Trust please visit www.hepctrust.org.uk

London Drug & Alcohol Policy Forum

The London Drug and Alcohol Policy Forum was established in 1991 and works to support policy and practice across London and encourage joint working. It is funded by the City of London Corporation.

acknowledgements

London Joint Working Group on
Substance Use and Hepatitis C
(LJWG)

Dr Kosh Agarwal

Ashwin Balabhadra

Dr Ashley Brown

Janet Catt

Viv Evans

Dr Emily Finch

Rachel Halford

Dr Magdalena Harris

Sarah Hart

John Jolly

Professor William Rosenberg

Dr Suman Verma

The LJWG would like to thank the following for their help and commitment to making today's event happen:

Jane Anson

Jane Cox

Dee Cunniffe

David Mackintosh

Aidan Rylatt

Urte Macikene

Addaction

Adfam

Blenheim

Change Grow Live

Consortio Healthcare

Lambeth Service User Council

LDAPF

Jon Derricot Films

Push Design and Print

Lorraine Hewitt House

Principle Consulting

The Hepatitis C Trust



#LJWG2018

LJWG.ORG.UK